Quantcast

Latest D-Mannitol Stories

2011-12-21 06:25:30

(Ivanhoe Newswire) — Adding inhaled powder mannitol to standard therapy for cystic fibrosis produced consistent lung function improvement for up to 52 weeks, according to this study. Mannitol treatment is not only efficient and safe, but it´s easy to administer as well. In the double-blind study, which was supported by Pharmaxis Limited, 318 patients were randomized to treatment with 400 mg bid inhaled mannitol or 50 mg bid inhaled mannitol (control group) for 26 weeks, followed...

2011-12-16 12:57:31

Adding inhaled dry powder mannitol to standard therapy for cystic fibrosis produced sustained improvement in lung function for up to 52 weeks, according to a new study. Along with the treatment's efficacy and good safety profile, the convenience and ease of administration of mannitol treatment may improve adherence with therapy in these patients. In the double-blind study, which was supported by Pharmaxis Limited, 318 patients were randomized to treatment with 400 mg bid inhaled mannitol...

2011-02-23 15:20:00

EXTON, Pa., Feb. 23, 2011 /PRNewswire/ -- Pharmaxis, a global specialty pharmaceutical company focused on therapeutic products for chronic respiratory and immune disorders, announced today the commercial launch of ARIDOL® (mannitol inhalation powder) Bronchial Challenge Test Kit, the first new bronchial challenge test in more than two decades and the company's first product launch in the U.S. ARIDOL is used to assess bronchial hyperresponsiveness in patients six years...

2010-11-10 16:31:00

EXTON, Pa., Nov. 10, 2010 /PRNewswire/ -- Pharmaxis, a global specialty pharmaceutical company focused on therapeutic products for respiratory and immune disorders, will present ARIDOL(TM) (mannitol inhalation powder) Bronchial Challenge Test Kit, at the 2010 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI), November 11-16 in Phoenix, AZ. Approved by the U.S. Food and Drug Administration (FDA) on October 5, 2010, ARIDOL is the first new bronchial...

2010-10-22 11:22:00

BALTIMORE, Oct. 22 /PRNewswire/ -- Pharmaceutical company Pharmaxis (ASX: PXS) today announced significant results of pooled data from its two large scale six month Phase III trials of Bronchitol (inhaled mannitol) in people with cystic fibrosis. The combined results have been presented for the first time at the North American Cystic Fibrosis Conference (NACFC) currently underway in Baltimore. In addition, more results from the second trial (CF302) have been released to supplement the...

2010-10-06 12:13:00

EXTON, Pa., Oct. 6 /PRNewswire/ -- Pharmaxis, a global specialty pharmaceutical company focused on therapeutic products for chronic respiratory and immune disorders, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market ARIDOL(TM) (mannitol inhalation powder) Bronchial Challenge Test Kit, the first new bronchial challenge test in more than two decades. ARIDOL is used for the assessment of bronchial hyperresponsiveness in patients six...

2009-05-04 03:02:00

SYDNEY, Australia, May 4 /PRNewswire-Asia-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) is pleased to announce positive results of its recently completed international Phase III trial of Bronchitol(TM) in people with cystic fibrosis. The study represents one of the largest clinical trials conducted in cystic fibrosis. The primary endpoint of the trial was to assess whether Bronchitol improves lung function as measured by a change in Forced Expiratory Volume...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related